tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2018 Jul 9:1-24. doi: 10.1080/21645515.2018.1489947. [Epub ahead of print]
[h=1]Passive immunization with influenza haemagglutinin specific monoclonal antibodies.[/h] Rudraraju R[SUP]1[/SUP], Subbarao K[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The isolation of broadly neutralising antibodies against the influenza haemagglutinin has spurred investigation into their clinical potential, and has led to advances in influenza virus biology and universal influenza vaccine development. Studies in animal models have been invaluable for demonstrating the prophylactic and therapeutic efficacy of broadly neutralizing antibodies, for comparisons with antiviral drugs used as the standard of care, and for defining their mechanism of action and potential role in providing protection from airborne infection.
[h=4]KEYWORDS:[/h] HA stem; Influenza; broadly neutralising antibodies; monoclonal antibodies; passive immunization
PMID: 29985756 DOI: 10.1080/21645515.2018.1489947
[h=1]Passive immunization with influenza haemagglutinin specific monoclonal antibodies.[/h] Rudraraju R[SUP]1[/SUP], Subbarao K[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The isolation of broadly neutralising antibodies against the influenza haemagglutinin has spurred investigation into their clinical potential, and has led to advances in influenza virus biology and universal influenza vaccine development. Studies in animal models have been invaluable for demonstrating the prophylactic and therapeutic efficacy of broadly neutralizing antibodies, for comparisons with antiviral drugs used as the standard of care, and for defining their mechanism of action and potential role in providing protection from airborne infection.
[h=4]KEYWORDS:[/h] HA stem; Influenza; broadly neutralising antibodies; monoclonal antibodies; passive immunization
PMID: 29985756 DOI: 10.1080/21645515.2018.1489947